Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR1915500.fastq.gz | Fastqsanger.gz | |||
| SRR1915510_1.fastq.gz | Fastqsanger.gz | |||
| SRR1915510_2.fastq.gz | Fastqsanger.gz | |||
| SRR1915491.fastq.gz | Fastqsanger.gz | |||
| SRR1915501.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 28 |
Similar Datasets
Project description:RNA-seq upon PAX8 knockdown in Renal Cell Carcinoma cell lines
2025-01-23 | E-MTAB-7808 | ExpressionAtlas
Project description:Treatment of renal cell carcinoma cell line A-498 with zebularine
2025-01-24 | E-GEOD-51627 | ExpressionAtlas
Project description:Smoking and Obesity Related Molecular Alterations in Clear Cell Renal Cell Carcinoma
2025-01-24 | E-GEOD-46699 | ExpressionAtlas
Project description:HLA ligand profiles of primary renal cell carcinoma maintained in metastases.sue
2025-01-24 | E-GEOD-12606 | ExpressionAtlas
Project description:Gene array analysis of clear cell renal cell carcinoma tissue versus matched normal kidney tissue
2025-01-24 | E-GEOD-53757 | ExpressionAtlas
Project description:Mus musculus Prcc, papillary renal cell carcinoma (translocation-associated) [Source:MGI Symbol;Acc:MGI:2137738], is differentially expressed in 54 experiment(s);
| ENSMUSG00000004895 | ExpressionAtlas
Project description:Mus musculus Prcc, papillary renal cell carcinoma (translocation-associated) [Source:MGI Symbol;Acc:MGI:2137738], is expressed in 37 baseline experiment(s);
| ENSMUSG00000004895 | ExpressionAtlas
Project description:Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment
Lisette dePillis 1, , Trevor Caldwell 2, , Elizabeth Sarapata 2, and Heather Williams 2,
1.
Department of Mathematics, Harvey Mudd College, Claremont, CA 91711
2.
Harvey Mudd College, Claremont, CA 91711, United States, United States, United States
Abstract
We present a mathematical model to study the effects of the regulatory T cells (Treg) on Renal Cell Carcinoma (RCC) treatment with sunitinib. The drug sunitinib inhibits the natural self-regulation of the immune system, allowing the effector components of the immune system to function for longer periods of time. This mathematical model builds upon our non-linear ODE model by de Pillis et al. (2009) [13] to incorporate sunitinib treatment, regulatory T cell dynamics, and RCC-specific parameters. The model also elucidates the roles of certain RCC-specific parameters in determining key differences between in silico patients whose immune profiles allowed them to respond well to sunitinib treatment, and those whose profiles did not.
Simulations from our model are able to produce results that reflect clinical outcomes to sunitinib treatment such as: (1) sunitinib treatments following standard protocols led to improved tumor control (over no treatment) in about 40% of patients; (2) sunitinib treatments at double the standard dose led to a greater response rate in about 15% the patient population; (3) simulations of patient response indicated improved responses to sunitinib treatment when the patient's immune strength scaling and the immune system strength coefficients parameters were low, allowing for a slightly stronger natural immune response.
Keywords: Renal cell carcinoma, mathematical modeling., sunitinib, immune system, regulatory T cells.
2024-09-02 | BIOMD0000000908 | BioModels
Project description:Homo sapiens KCCAT198, renal clear cell carcinoma-associated transcript 198 [Source:NCBI gene (formerly Entrezgene);Acc:105369954], is expressed in 24 baseline experiment(s);
| ENSG00000257642 | ExpressionAtlas
Project description:Homo sapiens LNCSRLR, lncRNA sorafenib resistance in renal cell carcinoma associated [Source:HGNC Symbol;Acc:HGNC:52753], is expressed in 34 baseline experiment(s);
| ENSG00000240032 | ExpressionAtlas